Haemonetics Corporation

Informe acción NYSE:HAE

Capitalización de mercado: US$4.8b

Salud financiera de hoja de balance de Haemonetics

Salud financiera controles de criterios 3/6

Haemonetics tiene un patrimonio de accionistas total de $943.3M y una deuda total de $871.1M, lo que sitúa su ratio deuda-patrimonio en 92.3%. Sus activos y pasivos totales son $2.2B y $1.3B respectivamente. El BAIT de Haemonetics es de $199.7M, por lo que su ratio de cobertura de intereses es de 22.6. Tiene efectivo e inversiones a corto plazo que ascienden a $195.1M.

Información clave

92.3%

Ratio deuda-patrimonio

US$871.06m

Deuda

Ratio de cobertura de intereses22.6x
EfectivoUS$195.12m
PatrimonioUS$943.32m
Total pasivoUS$1.26b
Activos totalesUS$2.20b

Actualizaciones recientes sobre salud financiera

Recent updates

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Jun 11

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

May 11
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Apr 01
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Jan 28
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Dec 20
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Oct 28
Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Oct 09
Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($765.0M) de HAE superan a sus pasivos a corto plazo ($261.8M).

Pasivo a largo plazo: Los activos a corto plazo ($765.0M) de HAE no cubren sus pasivos a largo plazo ($995.4M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de HAE (71.7%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de HAE ha crecido de 53.9% a 92.3% en los últimos 5 años.

Cobertura de la deuda: La deuda de HAE está bien cubierta por el flujo de caja operativo (22.6%).

Cobertura de intereses: Los pagos de intereses de la deuda de HAE están bien cubiertos por el BAIT (22.6x cobertura).


Hoja de balance


Descubre empresas con salud financiera